BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 8:55:00 PM | Browse: 692 | Download: 518
Publication Name World Journal of Gastroenterology
Manuscript ID 1173
Country/Territory China
2012-11-17 20:59
Peer-Review Started
2012-11-20 11:38
To Make the First Decision
2013-01-05 11:50
Return for Revision
2013-01-06 10:11
2013-01-24 14:28
Second Decision
2013-03-28 17:21
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-03-29 12:04
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-04-11 13:11
Typeset the Manuscript
2013-06-07 09:27
Publish the Manuscript Online
2013-06-14 23:10
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Autobiography
Article Title Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis
Manuscript Source Invited Manuscript
All Author List Guo-Cai Lv, Jin-Mei Yao, Yi-Da Yang, Lin Zheng, Ji-Fang Sheng, Yu Chen and Lan-Juan Li
Funding Agency and Grant Number
Funding Agency Grant Number
China National Science and Technology Major Project 2010ZB063
Health Department of Zhejiang Province, China 2010KYA067
Corresponding Author Lan-Juan Li, MD, PhD, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital of Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. ljli@mail.hz.zj.cn
Key Words Liver cirrhosis; Lamivudine; Adefovir dipivoxil; Efficacy; Alanine transaminase
Core Tip Present treatment guidelines advocate oral nucleos(t)ide analogues in decompensated chronic hepatitis B (CHB) patients. Studies with lamivudine (LAM) have demonstrated decreased mortality and improved liver function in CHB decompensated patients. However, LAM resistance mutations emerging during monotherapy can negate therapeutic benefit. Adefovir dipivoxil had no cross resistance with LAM. Consistent with outcomes in patients with LAM-resistance, no patient in de novo combination therapy group showed detectable resistance up to 144 wk in this study. The de novo combination therapy markedly improved liver function, reduced Child-Turcotte Pugh and Model for End-Stage Liver Disease scores in hepatitis B virus-related decompensated cirrhosis patients.
Publish Date 2013-06-14 23:10
Citation Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(22): 3481-3486
URL http://www.wjgnet.com/1007-9327/full/v19/i22/3481.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i22.3481
Full Article (PDF) WJG-19-3481.pdf
Manuscript File 1173-Review.doc
Answering Reviewers 1173-Answering reviewers.doc
Copyright License Agreement 1173-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 1173-Language cetificate.pdf
Peer-review Report 1173-Peer review.pdf
Scientific Editor Work List 1173-Scientific editor work list.doc